Patents by Inventor Mark Boldin

Mark Boldin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10435689
    Abstract: The present disclosure relates to the finding that microRNA-155 plays a role in inflammation, hematopoiesis and myeloproliferation, and that dysregulation of microRNA-155 expression is associated with particular myeloproliferative disorders. Disclosed herein are methods and compositions for diagnosing an treating disorders, including inflammation and myeloproliferation, modulating the levels of expression of one or more genes selected from the group consisting of Cutl1, Arntl, Picalm, Jarid2, PU.1, Csf1r, HIF1?, Sla, Cepb?, and Bach1, and the like.
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: October 8, 2019
    Assignee: California Institute of Technology
    Inventors: David Baltimore, Ryan M. O'Connell, Konstantin Taganov, Mark Boldin
  • Publication number: 20180187193
    Abstract: The present disclosure relates to the finding that microRNA-155 plays a role in inflammation, hematopoiesis and myeloproliferation, and that dysregulation of microRNA-155 expression is associated with particular myeloproliferative disorders. Disclosed herein are methods and compositions for diagnosing an treating disorders, including inflammation and myeloproliferation, modulating the levels of expression of one or more genes selected from the group consisting of Cutl1, Arntl, Picalm, Jarid2, PU.1, Csf1r, HIF1?, Sla, Cepb?, and Bach1, and the like.
    Type: Application
    Filed: December 5, 2017
    Publication date: July 5, 2018
    Inventors: David Baltimore, Ryan M. O'Connell, Konstantin Taganov, Mark Boldin
  • Patent number: 9862948
    Abstract: The present disclosure relates to the finding that microRNA-155 plays a role in inflammation, hematopoiesis and myeloproliferation, and that dysregulation of microRNA-155 expression is associated with particular myeloproliferative disorders. Disclosed herein are methods and compositions for diagnosing an treating disorders, including inflammation and myeloproliferation, modulating the levels of expression of one or more genes selected from the group consisting of Cutl1, Arnt1, Picalm, Jarid2, PU.1, Csf1r, HIF1?, Sla, Cebp?, and Bach1, and the like.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: January 9, 2018
    Assignee: California Institute of Technology
    Inventors: David Baltimore, Ryan M. O'Connell, Konstantin Taganov, Mark Boldin
  • Publication number: 20160244754
    Abstract: The present disclosure relates to the finding that microRNA-155 plays a role in inflammation, hematopoiesis and myeloproliferation, and that dysregulation of microRNA-155 expression is associated with particular myeloproliferative disorders. Disclosed herein are methods and compositions for diagnosing an treating disorders, including inflammation and myeloproliferation, modulating the levels of expression of one or more genes selected from the group consisting of Cutl1, Arnt1, Picalm, Jarid2, PU.1, Csf1r, HIF1?, Sla, Cepb?, and Bach1, and the like.
    Type: Application
    Filed: February 4, 2016
    Publication date: August 25, 2016
    Inventors: David Baltimore, Ryan M. O'Connell, Konstantin Taganov, Mark Boldin
  • Patent number: 9290761
    Abstract: The present disclosure relates to the finding that microRNA-155 plays a role in inflammation, hematopoiesis and myeloproliferation, and that dysregulation of microRNA-155 expression is associated with particular myeloproliferative disorders. Disclosed herein are methods and compositions for diagnosing an treating disorders, including inflammation and myeloproliferation, modulating the levels of expression of one or more genes selected from the group consisting of Cutl1, Arntl, Picalm, Jarid2, PU.1, Csflr, HIF1?, Sla, Cepb?, and Bach1, and the like.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: March 22, 2016
    Assignee: CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: David Baltimore, Ryan M. O'Connell, Konstantin Taganov, Mark Boldin
  • Patent number: 9090894
    Abstract: The present disclosure relates to the finding that microRNA-146 plays a role in modulating the development and function of the immune system. Immune cell development and function can be modulated by delivery of microRNA-146 (miR-146) or antisense miR-146 to target immune cells or precursor cells. For example, in some embodiments, activity and/or proliferation of certain immune cells is regulated by administering miR-146 oligonucleotides or anti-miR-146 oligonucleotides. In other embodiments, pro-inflammatory cytokine expression in immune cells is regulated by administering a miR-146 oligonucleotide or anti-miR-146. In further embodiments, methods of regulating macrophage activity using antisense miR-146 are provided. Additional methods and compositions for regulating immune system function and development using miR-146 are disclosed.
    Type: Grant
    Filed: December 17, 2008
    Date of Patent: July 28, 2015
    Assignee: CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: David Baltimore, Mark Boldin, Konstantin Taganov
  • Publication number: 20140220049
    Abstract: The present disclosure relates to the finding that microRNA-155 plays a role in inflammation, hematopoiesis and myeloproliferation, and that dysregulation of microRNA-155 expression is associated with particular myeloproliferative disorders. Disclosed herein are methods and compositions for diagnosing an treating disorders, including inflammation and myeloproliferation, modulating the levels of expression of one or more genes selected from the group consisting of Cutl1, Arntl, Picalm, Jarid2, PU.1, Csflr, HIFl?, Sla, Cepb?, and Bach1, and the like.
    Type: Application
    Filed: December 23, 2013
    Publication date: August 7, 2014
    Applicant: California Institute of Technology
    Inventors: David Baltimore, Ryan M. O'Connell, Konstantin Taganov, Mark Boldin
  • Patent number: 8697672
    Abstract: The present disclosure relates to the finding that microRNA-155 plays a role in inflammation, hematopoiesis and myeloproliferation, and that dysregulation of microRNA-155 expression is associated with particular myeloproliferative disorders. Disclosed herein are methods and compositions for diagnosing and treating disorders, including inflammation and myeloproliferation, modulating the levels of expression of one or more genes selected from the group consisting of Cutl1, Arnt1, Picalm, Jarid2, PU.1, Csf1r, HIF1?, Sla, Cepb?, and Bach1, and the like.
    Type: Grant
    Filed: May 16, 2008
    Date of Patent: April 15, 2014
    Assignee: California Institute of Technology
    Inventors: David Baltimore, Ryan O'Connell, Konstantin Taganov, Mark Boldin
  • Patent number: 8669235
    Abstract: The present disclosure relates to the finding that microRNA-146 plays a role modulating the innate immune response. Innate immunity receptor signaling can be modulated by delivery of microRNA-146 (miR-146) or antisense miR-146 to target immune cells. In some embodiments, IL-1 receptor associated kinase 1 (IRAK1) and TNF receptor associated factor 6 (TRAF6) expression levels are downregulated in a target cell by administering a miR-146 oligonucleotide. Modulation of the innate immune system through miR-146 can be used to treat a variety of diseases and disorders associated with activation of the innate immune system, such as sepsis and Crohn's disease.
    Type: Grant
    Filed: March 22, 2007
    Date of Patent: March 11, 2014
    Assignee: California Institute of Technology
    Inventors: David Baltimore, Mark Boldin, Konstantin Taganov
  • Patent number: 8236507
    Abstract: A DNA sequence encoding a protein capable of binding to a tumor necrosis factor receptor-associated factor (TRAF) molecule, TRAF-binding proteins, their isoforms, analogs, fragments and derivatives encoded by the DNA sequence, their methods for the production of the DNA sequences and proteins, and the uses for the DNA sequence and proteins.
    Type: Grant
    Filed: February 3, 2009
    Date of Patent: August 7, 2012
    Assignee: Yeda Research and Development Co., Ltd.
    Inventors: David Wallach, Nikolai Malinin, Mark Boldin, Andrei Kovalenko, Igor Mett
  • Publication number: 20110258716
    Abstract: The present disclosure relates to the finding that microRNA-146 plays a role in modulating the development and function of the immune system. Immune cell development and function can be modulated by delivery of microRNA-146 (miR-146) or antisense miR-146 to target immune cells or precursor cells. For example, in some embodiments, activity and/or proliferation of certain immune cells is regulated by administering miR-146 oligonucleotides or anti-miR-146 oligonucleotides. In other embodiments, pro-inflammatory cytokine expression in immune cells is regulated by administering a miR-146 oligonucleotide or anti-miR-146. In further embodiments, methods of regulating macrophage activity using antisense miR-146 are provided. Additional methods and compositions for regulating immune system function and development using miR-146 are disclosed.
    Type: Application
    Filed: June 1, 2011
    Publication date: October 20, 2011
    Applicant: CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: David Baltimore, Mark Boldin, Konstantin Taganov
  • Patent number: 7799901
    Abstract: The present invention provides proteins capable of modulating or mediating the FAS receptor ligand or TNF effect on cells carrying FAS receptor or p55 receptor by binding or interacting with MORT-1 protein, which in turn binds to the intracellular domain of the FAS receptor or to another protein TRADD which binds to the p55 receptor. In addition, peptide inhibitors that interfere with the proteolytic activity of MORT-1-binding proteins having proteolytic activity are provided, as well as a method of designing them.
    Type: Grant
    Filed: September 18, 2006
    Date of Patent: September 21, 2010
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: David Wallach, Mark Boldin, Tanya Goncharov, Yury V. Golstev
  • Publication number: 20090291888
    Abstract: A DNA sequence encoding a protein capable of binding to a tumor necrosis factor receptor-associated factor (TRAF) molecule, TRAF-binding proteins, their isoforms, analogs, fragments and derivatives encoded by the DNA sequence, their methods for the production of the DNA sequences and proteins, and the uses for the DNA sequence and proteins.
    Type: Application
    Filed: February 3, 2009
    Publication date: November 26, 2009
    Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
    Inventors: David Wallach, Nikolai Malinin, Mark Boldin, Andrei Kovalenko, Igor Mett
  • Publication number: 20090203136
    Abstract: The present disclosure relates to the finding that microRNA-146 plays a role in modulating the development and function of the immune system. Immune cell development and function can be modulated by delivery of microRNA-146 (miR-146) or antisense miR-146 to target immune cells or precursor cells. For example, in some embodiments, activity and/or proliferation of certain immune cells is regulated by administering miR-146 oligonucleotides or anti-miR-146 oligonucleotides. In other embodiments, pro-inflammatory cytokine expression in immune cells is regulated by administering a miR-146 oligonucleotide or anti-miR-146. In further embodiments, methods of regulating macrophage activity using antisense miR-146 are provided. Additional methods and compositions for regulating immune system function and development using miR-146 are disclosed.
    Type: Application
    Filed: December 17, 2008
    Publication date: August 13, 2009
    Inventors: David Baltimore, Mark Boldin, Konstantin Taganov
  • Patent number: 7485456
    Abstract: A DNA sequence encoding a protein capable of binding to a tumor necrosis factor receptor-associated factor (TRAF) molecule, TRAF-binding proteins, their isoforms, analogs, fragments and derivatives encoded by the DNA sequence, their methods for the production of the DNA sequences and proteins, and the uses for the DNA sequence and proteins.
    Type: Grant
    Filed: April 1, 1997
    Date of Patent: February 3, 2009
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: David Wallach, Nikolai Malinin, Mark Boldin, Andrei Kovalenko, Igor Mett
  • Publication number: 20080300211
    Abstract: The present disclosure relates to the finding that microRNA-155 plays a role in inflammation, hematopoiesis and myeloproliferation, and that dysregulation of microRNA-155 expression is associated with particular myeloproliferative disorders. Disclosed herein are methods and compositions for diagnosing and treating disorders, including inflammation and myeloproliferation, modulating the levels of expression of one or more genes selected from the group consisting of Cutl1, Arnt1, Picalm, Jarid2, PU.1, Csf1r, HIF1?, Sla, Cepb?, and Bach1, and the like.
    Type: Application
    Filed: May 16, 2008
    Publication date: December 4, 2008
    Inventors: David Baltimore, Ryan O'Connell, Konstantin Taganov, Mark Boldin
  • Patent number: 7323548
    Abstract: Proteins capable of modulating the function of FAS/APO1 are provided. The proteins may be prepared by culturing a host cell transformed with a vector containing the DNA encoding such a protein under suitable conditions and isolating the protein.
    Type: Grant
    Filed: August 23, 2004
    Date of Patent: January 29, 2008
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: David Wallach, Mark Boldin, Eugene Varfolomeev, Igor Mett
  • Publication number: 20070232520
    Abstract: The present invention generally concerns novel proteins which bind to the intracellular domains of the p55 and p75 TNF-Rs and the FAS-R, which are capable of modulating the function of the p55 and p75 TNF-Rs and the FAS-R, and the DNA sequences which encode them. The present invention also concerns new soluble oligomeric TNF-Rs, oligomeric FAS-Rs and oligomeric receptors having a mixture of TNF-Rs and FAS-Rs. In addition, the present invention concerns methods of preparation and uses of all of the aforementioned.
    Type: Application
    Filed: December 22, 2006
    Publication date: October 4, 2007
    Applicant: Yeda Research and Development Co., Ltd.
    Inventors: David WALLACH, Mark Boldin, Igor Mett, Eugene Varfolomeev
  • Publication number: 20070232553
    Abstract: The present disclosure relates to the finding that microRNA-146 plays a role modulating the innate immune response. Innate immunity receptor signaling can be modulated by delivery of microRNA-146 (miR-146) or antisense miR-146 to target immune cells. In some embodiments, IL-1 receptor associated kinase 1 (IRAK1) and TNF receptor associated factor 6 (TRAF6) expression levels are downregulated in a target cell by administering a miR-146 oligonucleotide. Modulation of the innate immune system through miR-146 can be used to treat a variety of diseases and disorders associated with activation of the innate immune system, such as sepsis and Crohn's disease.
    Type: Application
    Filed: March 22, 2007
    Publication date: October 4, 2007
    Applicant: California Institute of Technology
    Inventors: David Baltimore, Mark Boldin, Konstantin Taganov
  • Publication number: 20070166787
    Abstract: A modulator of regulatory cellular events occurring intracellularly which are mediated by regulatory proteins containing a ‘death domain’ motif is provided. The ‘death domain’ is a regulatory portion of the regulatory proteins, and the modulator is capable of interacting with one or more ‘death domain’ motifs contained in the regulatory proteins and affecting the regulatory action of one or more of the regulatory proteins. The modulator preferably is capable of interacting with ‘death domain’ motifs within p55-TNF-R, FAS/APO1-R, NGF-R, MORT-1, RIP, TRADD, or ankyrin. A method for producing the modulators is also provided. The modulators are useful for modulating functions mediated in cells by proteins containing the ‘death domain’.
    Type: Application
    Filed: August 29, 2006
    Publication date: July 19, 2007
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: David Wallach, Mark Boldin, Eugene Varfolomeev, Zeev Pancer, Igor Mett, Tanya Goncharov